Granulocyte colony-stimulating factor

Colony stimulating factor 3 (granulocyte)

Ribbon diagram showing three molecules of human G-CSF. From PDB: 1rhg​
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols CSF3 ; C17orf33; CSF3OS; GCSF
External IDs OMIM: 138970 MGI: 1339751 HomoloGene: 7677 GeneCards: CSF3 Gene
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 1440 12985
Ensembl ENSG00000108342 ENSMUSG00000038067
UniProt P09919 P09920
RefSeq (mRNA) NM_000759 NM_009971
RefSeq (protein) NP_000750 NP_034101
Location (UCSC) Chr 17:
40.02 – 40.02 Mb		 Chr 11:
98.7 – 98.7 Mb
PubMed search

Granulocyte-colony stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. The pharmaceutical analogs of naturally occurring G-CSF are called filgrastim and lenograstim.

G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.

Discovery

Mouse granulocyte-colony stimulating factor (G-CSF) was first recognised and purified in Walter and Eliza Hall Institute, Australia in 1983,[1] and the human form was cloned by groups from Japan and Germany/United States in 1986.[2][3]

Biological function

G-CSF is produced by endothelium, macrophages, and a number of other immune cells. The natural human glycoprotein exists in two forms, a 174- and 177-amino-acid-long protein of molecular weight 19,600 grams per mole. The more-abundant and more-active 174-amino acid form has been used in the development of pharmaceutical products by recombinant DNA (rDNA) technology.

White blood cells
The G-CSF-receptor is present on precursor cells in the bone marrow, and, in response to stimulation by G-CSF, initiates proliferation and differentiation into mature granulocytes. G-CSF stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils. G-CSF regulates them using Janus kinase (JAK)/signal transducer and activator of transcription (STAT) and Ras/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signal transduction pathway.
hematopoietic system
G-CSF is also a potent inducer of HSCs mobilization from the bone marrow into the bloodstream, although it has been shown that it does not directly affect the hematopoietic progenitors that are mobilized.[4]
Neurons
G-CSF can also act on neuronal cells as a neurotrophic factor. Indeed, its receptor is expressed by neurons in the brain and spinal cord. The action of G-CSF in the central nervous system is to induce neurogenesis, to increase the neuroplasticity and to counteract apoptosis.[5][6] These properties are currently under investigations for the development of treatments of neurological diseases such as cerebral ischemia.

Genetics

The gene for G-CSF is located on chromosome 17, locus q11.2-q12. Nagata et al. found that the GCSF gene has 4 introns, and that 2 different polypeptides are synthesized from the same gene by differential splicing of mRNA.[2]

The 2 polypeptides differ by the presence or absence of 3 amino acids. Expression studies indicate that both have authentic GCSF activity.

It is thought that stability of the G-CSF mRNA is regulated by an RNA element called the G-CSF factor stem-loop destabilising element.

Therapeutic use

Chemotherapy induced neutropenia

Chemotherapy can cause myelosuppression and unacceptably low levels of white blood cells (neutropenia), making patients susceptible to infections and sepsis. G-CSF stimulates the production of granulocytes, a type of white blood cell. In oncology and hematology, a recombinant form of G-CSF is used with certain cancer patients to accelerate recovery from neutropenia after chemotherapy, allowing higher-intensity treatment regimens. It is administered to oncology patients via subcutaneous or intravenous routes.[7]

A study in mice has shown that G-CSF may decrease bone mineral density.[8]

Before blood donation

G-CSF is also used to increase the number of hematopoietic stem cells in the blood of the donor before collection by leukapheresis for use in hematopoietic stem cell transplantation. For this purpose, G-CSF appears to be safe in pregnancy during implantation as well as during the second and third trimesters.[9] Breastfeeding should be withheld for 3 days after CSF administration to allow for clearance of it from the milk.[9] People who have been administered colony-stimulating factors do not have a higher risk of leukemia than people who have not.[9]

Stem cell transplants

G-CSF may also be given to the receiver in hematopoietic stem cell transplantation, to compensate for conditioning regimens.

Research

G-CSF when given early after exposure to radiation may improve white blood cell counts, and is stockpiled for use in radiation incidents.[10][11]

Itescu planned in 2004 to use G-CSF to treat heart degeneration by injecting it into the blood-stream, plus SDF (stromal cell-derived factor) directly to the heart.[12]

Due to its neuroprotective properties, G-CSF is currently under investigation for cerebral ischemia in a clinical phase IIb [13] and several clinical pilot studies are published for other neurological disease such as amyotrophic lateral sclerosis.[14]

Side effect

Sweet's syndrome is a known side effect of using this drug.[15]

Pharmaceutical variants

It was first marketed by Amgen with the brand name Neupogen. Several bio-generic versions are now also available in markets such as Europe and Australia.

The recombinant human G-CSF (rhG-CSF) synthesised in an E. coli expression system is called filgrastim. The structure of filgrastim differs slightly from the structure of the natural glycoprotein. Most published studies have used filgrastim. Filgrastim (Neupogen) and PEG-filgrastim (Neulasta) are two commercially-available forms of rhG-CSF. The PEG (polyethylene glycol) form has a much longer half-life, reducing the necessity of daily injections.

Another form of rhG-CSF called lenograstim is synthesised in Chinese Hamster Ovary cells (CHO cells). As this is a mammalian cell expression system, lenograstim is indistinguishable from the 174-amino acid natural human G-CSF. No clinical or therapeutic consequences of the differences between filgrastim and lenograstim have yet been identified, but there are no formal comparative studies.

See also

References

  1. ↑ Metcalf D (Jul 1985). "The granulocyte-macrophage colony-stimulating factors". Science 229 (4708): 16–22. doi:10.1126/science.2990035. PMID 2990035.
  2. 1 2 Nagata S, Tsuchiya M, Asano S, Kaziro Y, Yamazaki T, Yamamoto O, Hirata Y, Kubota N, Oheda M, Nomura H (1986). "Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor". Nature 319 (6052): 415–8. doi:10.1038/319415a0. PMID 3484805.
  3. ↑ Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK (Apr 1986). "Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells". Science 232 (4746): 61–5. doi:10.1126/science.2420009. PMID 2420009.
  4. ↑ Thomas J, Liu F, Link DC (May 2002). "Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor". Current Opinion in Hematology 9 (3): 183–9. doi:10.1097/00062752-200205000-00002. PMID 11953662.
  5. ↑ Schneider A, Krüger C, Steigleder T, Weber D, Pitzer C, Laage R, Aronowski J, Maurer MH, Gassler N, Mier W, Hasselblatt M, Kollmar R, Schwab S, Sommer C, Bach A, Kuhn HG, Schäbitz WR (Aug 2005). "The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis". The Journal of Clinical Investigation 115 (8): 2083–98. doi:10.1172/JCI23559. PMC 1172228. PMID 16007267.
  6. ↑ Pitzer C, Krüger C, Plaas C, Kirsch F, Dittgen T, Müller R, Laage R, Kastner S, Suess S, Spoelgen R, Henriques A, Ehrenreich H, Schäbitz WR, Bach A, Schneider A (Dec 2008). "Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis". Brain 131 (Pt 12): 3335–47. doi:10.1093/brain/awn243. PMC 2639207. PMID 18835867.
  7. ↑ "Granulocyte colony stimulating factor (G-CSF)". Cancer Research UK. Retrieved 12 November 2014.
  8. ↑ Hirbe AC, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K (Apr 2007). "Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner". Blood 109 (8): 3424–31. doi:10.1182/blood-2006-09-048686. PMC 1852257. PMID 17192391.
  9. 1 2 3 Pessach I, Shimoni A, Nagler A (2013). "Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know?". Human Reproduction Update 19 (3): 259–67. doi:10.1093/humupd/dms053. PMID 23287427.
  10. ↑ Weisdorf D, Chao N, Waselenko JK, Dainiak N, Armitage JO, McNiece I, Confer D (Jun 2006). "Acute radiation injury: contingency planning for triage, supportive care, and transplantation". Biology of Blood and Marrow Transplantation 12 (6): 672–82. doi:10.1016/j.bbmt.2006.02.006. PMID 16737941.
  11. ↑ Weinstock DM, Case C, Bader JL, Chao NJ, Coleman CN, Hatchett RJ, Weisdorf DJ, Confer DL (Jun 2008). "Radiologic and nuclear events: contingency planning for hematologists/oncologists". Blood 111 (12): 5440–5. doi:10.1182/blood-2008-01-134817. PMC 2424146. PMID 18287516.
  12. ↑ Finkel, Elizabeth (2005). Stem cells: controversy on the frontiers of science. Crows Nest: ABC Books. ISBN 0-7333-1248-9.
  13. ↑ http://clinicaltrials.gov/ct/show/NCT00927836
  14. ↑ Zang Y et al. Amyotroph Lateral Scler. 2008 Dec 4:1-2 Preliminary investigation of effect of granulocyte colony stimulating factor on amyotrophic lateral sclerosis.
  15. ↑ Paydaş S, Sahin B, Seyrek E, Soylu M, Gonlusen G, Acar A, Tuncer I (Sep 1993). "Sweet's syndrome associated with G-CSF". British Journal of Haematology 85 (1): 191–2. doi:10.1111/j.1365-2141.1993.tb08668.x. PMID 7504506.

Further reading

  • Duarte RF, Franf DA (Jun 2002). "The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF): molecular basis and clinical relevance". Leukemia & Lymphoma 43 (6): 1179–87. doi:10.1080/10428190290026231. PMID 12152985. 
  • Mroczko B, Szmitkowski M (2005). "Hematopoietic cytokines as tumor markers". Clinical Chemistry and Laboratory Medicine 42 (12): 1347–54. doi:10.1515/CCLM.2004.253. PMID 15576295. 
  • Sallerfors B, Olofsson T (Oct 1992). "Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) secretion by adherent monocytes measured by quantitative immunoassays". European Journal of Haematology 49 (4): 199–207. doi:10.1111/j.1600-0609.1992.tb00047.x. PMID 1281454. 
  • Zink T, Ross A, Ambrosius D, Rudolph R, Holak TA (Dec 1992). "Secondary structure of human granulocyte colony-stimulating factor derived from NMR spectroscopy". FEBS Letters 314 (3): 435–9. doi:10.1016/0014-5793(92)81521-M. PMID 1281794. 
  • Kubota N, Orita T, Hattori K, Oh-eda M, Ochi N, Yamazaki T (Mar 1990). "Structural characterization of natural and recombinant human granulocyte colony-stimulating factors". Journal of Biochemistry 107 (3): 486–92. PMID 1692828. 
  • Nagata S, Tsuchiya M, Asano S, Yamamoto O, Hirata Y, Kubota N, Oheda M, Nomura H, Yamazaki T (Mar 1986). "The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor". The EMBO Journal 5 (3): 575–81. PMC 1166801. PMID 2423327. 
  • Simmers RN, Smith J, Shannon MF, Wong G, Lopez AF, Baker E, Sutherland GR, Vadas MA (Feb 1988). "Localization of the human G-CSF gene to the region of a breakpoint in the translocation typical of acute promyelocytic leukemia". Human Genetics 78 (2): 134–6. doi:10.1007/BF00278182. PMID 2448221. 
  • Tweardy DJ, Cannizzaro LA, Palumbo AP, Shane S, Huebner K, Vantuinen P, Ledbetter DH, Finan JB, Nowell PC, Rovera G (Aug 1987). "Molecular cloning and characterization of a cDNA for human granulocyte colony-stimulating factor (G-CSF) from a glioblastoma multiforme cell line and localization of the G-CSF gene to chromosome band 17q21". Oncogene Research 1 (3): 209–20. PMID 2453015. 
  • Tsuchiya M, Nomura H, Asano S, Kaziro Y, Nagata S (Mar 1987). "Characterization of recombinant human granulocyte-colony-stimulating factor produced in mouse cells". The EMBO Journal 6 (3): 611–6. PMC 553441. PMID 3034599. 
  • Devlin JJ, Devlin PE, Myambo K, Lilly MB, Rado TA, Warren MK (Apr 1987). "Expression of granulocyte colony-stimulating factor by human cell lines". Journal of Leukocyte Biology 41 (4): 302–6. PMID 3494801. 
  • Kanda N, Fukushige S, Murotsu T, Yoshida MC, Tsuchiya M, Asano S, Kaziro Y, Nagata S (Nov 1987). "Human gene coding for granulocyte-colony stimulating factor is assigned to the q21-q22 region of chromosome 17". Somatic Cell and Molecular Genetics 13 (6): 679–84. doi:10.1007/BF01534488. PMID 3499671. 
  • Le Beau MM, Lemons RS, Carrino JJ, Pettenati MJ, Souza LM, Diaz MO, Rowley JD (Dec 1987). "Chromosomal localization of the human G-CSF gene to 17q11 proximal to the breakpoint of the t(15;17) in acute promyelocytic leukemia". Leukemia 1 (12): 795–9. PMID 3501046. 
  • Zink T, Ross A, Lüers K, Cieslar C, Rudolph R, Holak TA (Jul 1994). "Structure and dynamics of the human granulocyte colony-stimulating factor determined by NMR spectroscopy. Loop mobility in a four-helix-bundle protein". Biochemistry 33 (28): 8453–63. doi:10.1021/bi00194a009. PMID 7518249. 
  • Corcione A, Baldi L, Zupo S, Dono M, Rinaldi GB, Roncella S, Taborelli G, Truini M, Ferrarini M, Pistoia V (Oct 1994). "Spontaneous production of granulocyte colony-stimulating factor in vitro by human B-lineage lymphocytes is a distinctive marker of germinal center cells". Journal of Immunology 153 (7): 2868–77. PMID 7522243. 
  • Watari K, Ozawa K, Tajika K, Tojo A, Tani K, Kamachi S, Harigaya K, Takahashi T, Sekiguchi S, Nagata S (Jul 1994). "Production of human granulocyte colony stimulating factor by various kinds of stromal cells in vitro detected by enzyme immunoassay and in situ hybridization". Stem Cells 12 (4): 416–23. doi:10.1002/stem.5530120409. PMID 7524894. 
  • Hill CP, Osslund TD, Eisenberg D (Jun 1993). "The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors". Proceedings of the National Academy of Sciences of the United States of America 90 (11): 5167–71. doi:10.1073/pnas.90.11.5167. PMC 46676. PMID 7685117. 
  • Haniu M, Horan T, Arakawa T, Le J, Katta V, Rohde MF (Dec 1995). "Extracellular domain of granulocyte-colony stimulating factor receptor. Interaction with its ligand and identification of a domain in close proximity of ligand-binding region". Archives of Biochemistry and Biophysics 324 (2): 344–56. doi:10.1006/abbi.1995.0047. PMID 8554326. 
  • McCracken S, Layton JE, Shorter SC, Starkey PM, Barlow DH, Mardon HJ (May 1996). "Expression of granulocyte-colony stimulating factor and its receptor is regulated during the development of the human placenta". The Journal of Endocrinology 149 (2): 249–58. doi:10.1677/joe.0.1490249. PMID 8708536. 

External links

This article is issued from Wikipedia - version of the Thursday, April 28, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.